Contrasting SI-Bone (NASDAQ:SIBN) & Its Peers

SI-Bone (NASDAQ: SIBN) is one of 121 public companies in the “Surgical & medical instruments” industry, but how does it contrast to its peers? We will compare SI-Bone to related companies based on the strength of its profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and earnings.

Analyst Ratings

This is a summary of current ratings and price targets for SI-Bone and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SI-Bone 0 0 4 0 3.00
SI-Bone Competitors 814 2815 4988 252 2.53

SI-Bone presently has a consensus target price of $24.75, suggesting a potential upside of 63.58%. As a group, “Surgical & medical instruments” companies have a potential upside of 29.01%. Given SI-Bone’s stronger consensus rating and higher possible upside, analysts plainly believe SI-Bone is more favorable than its peers.

Profitability

This table compares SI-Bone and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SI-Bone N/A N/A N/A
SI-Bone Competitors -30.00% -41.48% -13.59%

Insider and Institutional Ownership

39.5% of SI-Bone shares are owned by institutional investors. Comparatively, 50.8% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 15.9% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares SI-Bone and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
SI-Bone $55.38 million -$17.45 million -21.31
SI-Bone Competitors $1.48 billion $146.48 million 39.08

SI-Bone’s peers have higher revenue and earnings than SI-Bone. SI-Bone is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

SI-Bone Company Profile

SI-BONE, Inc., a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.

Receive News & Ratings for SI-Bone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-Bone and related companies with MarketBeat.com's FREE daily email newsletter.